Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.520 +0.0% SGN 0.255 +0.0% CNC 1.49 +1.4% PHNM 0.345 +6.2% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.520 +0.0% SGN 0.255 +0.0% CNC 1.49 +1.4% PHNM 0.345 +6.2%
Earnings

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of

By The Northwire Desk — AI Analysis Aug 07, 2025 · 07:00 QNTM · 36.00 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma reported financial and operational results for Q2 2025, highlighting a strengthened balance sheet with total assets increasing to $15.3 million USD and the elimination of all debenture liabilities through conversion to equity.
  • The company announced significant progress in its drug pipeline, including positive Phase 1 oral toxicity results for Lucid-MS (Multiple Sclerosis) and the receipt of ethics approval for a Phase 2 trial of FSD202 (Mast Cell Activation Syndrome).
  • Unbuzzd Wellness Inc., the licensee for the company's alcohol recovery asset, launched a Regulation D 506(c) offering to raise up to $5.0 million USD for growth and a potential IPO, which will not dilute Quantum BioPharma shareholders.

Key Details

  • Financial Position:
    • Total current assets: $10.3 million USD (up from $9.9 million USD in Q1 2025).
    • Total assets: $15.3 million USD (up from $14.9 million USD in Q1 2025).
    • Operating expenses: $4.9 million USD (up from $3.4 million USD in Q1 2025, driven by share-based payments and legal/administrative costs).
    • External R&D fees: $0.6 million USD (down from $1.7 million USD in Q1 2025).
    • Debt Status: All debentures from Q4 2024 and Q1 2025 converted to Class B shares; no outstanding convertible debt liability.
    • Warrants: A warrant liability of $7.8 million USD was recorded as a non-cash accounting transaction, but all outstanding warrants have since been exercised, eliminating the liability.
    • Cash Flow/Liquidity: Management states there is sufficient cash on hand to maintain basic operations beyond March 2027.
  • Legal Settlements:
    • Received a settlement payment of $2.35 million USD related to a legal process concerning the former CEO.
    • Sports Coat litigation loan fully repaid with a full release received.
  • Cryptocurrency Holdings:
    • Total purchases of Bitcoin (BTC) and other cryptocurrencies amount to approximately $5.5 million USD.
    • Unrealized and realized gains in cryptocurrency exceed $500,000 USD.
  • Lucid-MS (Multiple Sclerosis) Updates:
    • Phase 1 oral toxicity studies completed with no toxicity or side effects reported.
    • First MS patient scanned in a joint study with Massachusetts General Hospital using a novel PET imaging technique to monitor demyelination.
    • Agreement signed with a global pharmaceutical CRO to prepare an Investigational New Drug (IND) application package for the US FDA.
  • FSD202 (Mast Cell Activation Syndrome) Updates:
    • Received ethics approval from the Human Ethics Review Committee (HERC) in Australia for a Phase 2 randomized, double-blind, placebo-controlled trial.
  • Unbuzzd Wellness Inc. (Licensee Updates):
    • Launched a Regulation D 506(c) offering to raise up to $5.0 million USD for growth, distribution, and a go-public event.
    • Hired MNP as auditors to prepare for a possible IPO.
    • Awaiting Health Canada approval to sell unbuzzd in Canada.
    • Sales of unbuzzd powder sticks in the USA are increasing organically quarter-over-quarter.
  • Shareholder Structure:
    • Total Class B Subordinate Voting Shares issued and outstanding: 3,815,835.
    • 66% held through depository nominees (CEDE & Co. and CDS & Co.).
    • 34% held by registered holders.

Notable Quotes

  • “I am elated that we have finished the second quarter of 2025 in an even stronger position than at close of Q1 2025. The second quarter of 2025 was highlighted by a stronger balance sheet, continued delivery of efficiencies, and continued development of our robust pipeline of products and assets focused on addressing significant unmet needs in brain disorders and alcohol health, with three potential near-term monetization events.” — Zeeshan Saeed, CEO
  • “We also made significant progress with our MS program. Our recently announced partnership with Massachusetts General Hospital scientists is underway with the first patient having undergone PET scanning utilizing a potentially breakthrough diagnostic protocol for monitoring demyelination related to MS.” — Zeeshan Saeed, CEO
  • “We currently have significant unrealized profits in our crypto portfolio, and we continue to manage our treasury risk with this diversification.” — Zeeshan Saeed, CEO
Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other